AbbVie (ABBV) Q4 2024 Earnings Call Transcript
Welcome to the AbbVie fourth-quarter 2024 Earnings Conference Call. [Operator instructions] Today's call is also being recorded. If you have any objections, you may disconnect at this time. I would ...
AbbVie's Skyrizi and Rinvoq Have Revived Growth Beyond Humira, Supporting a Wide Moat
AbbVie's acquisition of Allergan significantly increased the firm's debt level. We expect the firm's net debt position to peak at close to $70 billion in 2020 but given the strong cash flows of AbbVie ...
AbbVie targets $24B in 2025 sales from Skyrizi and Rinvoq, outlines robust mid-single-digit growth
He emphasized the consistent outperformance of the ex-Humira platform, which grew over 18% annually and accelerated to 22% growth in Q4. The company projects mid-single-digit revenue growth in 2025, ...
AbbVie forecasts 2025 profit above estimates on newer immunology drugs
By Christy Santhosh and Puyaan Singh (Reuters) -AbbVie forecast 2025 profit above estimates on Friday, as strong sales of its ...
AbbVie's newer immunology drugs are offsetting Humira's decline, sending stock up 5%
AbbVie Inc.'s stock rose 7.7% Friday to lead S&P 500 gainers after the drug company beat fourth-quarter earnings estimates and offered an upbeat view of 2025, as its newer immunology drugs delivered ...